Skip to main content

Can we trust a vaccine that's been rushed through?

For a vaccine to reach the general public it will have to work and be safe.
There may be a misconception that vaccine research takes a long time but it isn’t just the research that takes the time – it’s all the steps beforehand, like getting funding and getting approved. What’s sped up in the development of a COVID-19 vaccine is the funding.
The UK Government funded development of COVID-19 vaccine clinical trials to get them up and running quickly. 
The Medicines and Healthcare Products Regulatory Agency (MHRA) and Medicines Research Authority have sped up the process of approval – things like administrative paperwork that used to take months is now being done in days. This is what’s brought down the time for delivery of the clinical trials. 
Processes have been streamlined and run in parallel.
It has also been helped by new technology, including the ability to rapidly manufacture vaccines. And supply – the vaccine started to be produced so that as soon as it was known to be safe and effective it could be made available.
The first vaccine to be approved by the MHRA was tested in a trial of over 40,000 adults, was shown to be 95 per cent effective after two doses, and was effective in all groups in the trial.
Like all medicines, vaccines can cause side effects. Most of these are mild and short-term, and not everyone gets them.

The MHRA publish weekly vaccine safety reports. This reassuring data shows that the vast majority of reported side effects are mild and all are in line with most types of vaccine, including the seasonal flu vaccine. These include sore arms and mild ‘flu-like’ symptoms, which reflect a normal immune response to vaccines and are short-lasting. These MHRA reports are available here: